Clinical

Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.

All-cause mortality in patients with chronic obstructive pulmonary disease is improved by a high level of continuity of care.

What we're reading, December 17, 2015: Congress is expected to pass a spending plan that includes 3 changes to the Affordable Care Act; a new analysis estimates 2016 premiums for marketplace plans will increase 11%; and one-third of Americans die from cardiovascular disease.

A study in the Journal of Clinical Oncology predicts financial stress on Medicare Part D beneficiaries on oral anticancer medicines, even after the expected closing of the donut hole in 2020.

Martin Shkreli, Turing CEO, was arrested on fraud related to his time as a hedge fund manager, not his recent price gouging of Daraprim.

NICE rejects promising oncology agents once again, citing high drug cost.

Several new FDA approvals and research advances in oncology have the potential for improved outcomes among cancer patients.

A retrospective analysis of phase 1 oncology studies that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development and biopsy sample collection.

The FDA, today, launched precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

What we're reading, December 15, 2015: call centers overwhelmed by last-minute rush for health insurance enrollment; AstraZeneca exploring deal with Acerta Pharma; and despite near universal health insurance coverage in Massachusetts, patients have access issues.

A report by STAT has found that a majority of institutions conducting clinical trials fail to report their results to the website ClinicalTrials.gov.

There is, currently, an unmet need in bladder cancer, a disease expected to be responsible for 16,000 deaths in 2015.

What we're reading, December 14, 2015: public health initiatives are underfunded despite being a big return on investment; the FDA repeatedly approved the cancer drug Afinitor without proof it extended life; and a nurse may have exposed patients in a maternity wing to tuberculosis.

Stacey W. McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology, discussed strategies for managing high-cost treatments, the impact of me-too drugs, and how clinical pathways can help physicians make treatment decisions at the point of care.

Despite recommendations that all healthcare workers are vaccinated against the flu, a study from the University of Michigan found that more than half of hospitals do not require healthcare providers get the influenza vaccine.

Within 3 months of being granted priority review, alectinib (Alecensa) has been approved for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed or who cannot tolerate crizotinib

When considering how to rectify the rising prices of drugs, there are a number of interventions at multiple levels that can work to decrease costs to patients and the price of the drug, explained Yousuf Zafar, MD, MHS, associate professor in the Division of Medical Oncology at Duke Cancer Institute.

Solutions proposed by patient advocates and physicians to control costs provide approaches to valuing new drug/treatments compared with 1 or several prevailing standards of care. Increasingly, however, the debate over cost is transitioning to a debate over value.

On Tuesday, December 15, from 11 am to noon EST, The American Journal of Managed Care will host a tweetchat with Leah Binder, MA, MGA, president and CEO of The Leapfrog Group, about hospital quality ratings, patient safety, and healthcare outcomes.

Research conducted at the Yale Cancer Center has found that a procedure known as cavity shave margins could avoid unnecessary follow-up surgeries and save time and costs.

Research presented during a health outcomes session at the recently concluded annual meeting of the American Society of Hematology evaluated the influence of patients’ insurance status on clinical outcomes of CML.

The DigniCap Cooling System reduces the frequency and severity of alopecia during chemotherapy in breast cancer patients.

The workgroup that generated the guideline included experts in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing, along with a cancer survivor who provided a patient perspective.

As Americans continue to struggle to afford their medical bills, and some newly insured under the Affordable Care Act find they can’t afford to use the coverage they purchased, finding the “right” health insurance plan is important.

During the 5-year value-based insurance design demonstration in Medicare Advantage, the hope is that the models will show that lower cost-sharing for high-value services and providers meets the triple aim, explained A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.